Home › Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma
 

Keywords :   


Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma

2015-07-01 08:13:50| drugdiscoveryonline Home Page

Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma

Tags: trial clinical collaboration announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05New ACA-Published Industry Market Analysis for the Paint & Coatings Industry Now Available
20.05Ulta Beauty Launches Same-Day Delivery with DoorDash
20.05Nivea Crmes Limited-Edition Pride Tin Heralds New Initiative with PFLAG
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
20.05Scentair Adds Two Odor-Neutralizing Fragrances to its Auto Line Up
20.05GK Hair Unveils Summer 2024s Must-Have Hair Trends
20.05Revlon Taps Under Armour\'s Tchernavia Rocker As New Chief People Officer
20.05Canada invests over $9.6M to prevent, prepare for African swine fever
More »